Presentation on theme: "GOLD-Assembly Berlin 2008 J Mark FitzGerald. Health outcomes in COPD: the importance of economic evaluations. J Mark FitzGerald Carlo Marra."— Presentation transcript:
GOLD-Assembly Berlin 2008 J Mark FitzGerald
Health outcomes in COPD: the importance of economic evaluations. J Mark FitzGerald Carlo Marra
What it is!
The Holy Trinity Of Economics 1.Resources are always and everywhere scarce, limited, finite 2.There are more beneficial programmes than we have resources to do 3.Choices must therefore be made and opportunities (alternatives that we might have done) forgone –Applies to all levels of human decision making: Individual decisions (e.g., time allocation) Health care decisions (AIDS vs. arthritis) Macro economy decisions (defense vs. health) –Efficient allocation of resources is where opportunity costs are minimized (i.e. we are getting the greatest value from our resources )
Health Economic Evaluations Are Just One Part of Health Economics HealthEconomics Health Economic Evaluation Other topics in health economics: optimal size of hospitals, optimal payment for physicians, optimal level of co-payment by patients,….
Economic Evaluation Cost analysis – Do not include outcomes – Focus on resource utilization and costs – Not a full economic analysis Cost-benefit analysis –Both costs and effects measured in $ – Rarely used in health Cost-effectiveness analysis (CEA) Cost-utility analysis (CUA)
Cost Effectiveness Analysis Bang for buck –Compare programs in terms of their cost per outcome (effect) Single measure of effect –Natural units (e.g. cases detected or prevented) Incremental form –Ratio of additional cost to additional benefit
Cost-Effectiveness Ratio Compares a specific (new) intervention to a stated alternative (old) intervention (Cost new – Cost old ) / (Benefit new – Benefit old ) Incremental resources required by the intervention Incremental health effects gained by using the intervention
Health economics and COPD: Overview of health economics. Overview of health economics. Program evaluation. Program evaluation. Cost effectiveness of interventions. Cost effectiveness of interventions. Perspective: Perspective: – Government – Patient. – Society
Economic costs of COPD exacerbations (1). n RUSIC prospectively tracked all exacerbations in a cohort of COPD patients in one year. n Data on exacerbations and health care utilization captured.609 subjects followed. n 678 Visits, 245 ED visits. n 151 hospitalizations. Mittmann and FitzGerald et al Resp Med 2008
Economic costs of COPD exacerbations (2) n Moderate exacerbation costs: $641 ($126 Out pt. and $515 ED) n Severe exacerbation:$7,060 ± 10,826. n National burden related to estimated 60,000 COPD hospitalizations in Canada: burden of ME and SE $646 million. Mittmann and FitzGerald et al Resp Med 2008
Annual cost of asthma in BC by year and cost component Cohort 155,000 asthma patients: (2006 CAN$) FitzGerald and Marra
Annual cost of asthma by category 94% of costs caused by uncontrolled patients FitzGerald and Marra